PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 2, 2025Siberian Journal of Oncology1 citationsOpen Access

Efficacy of Neoadjuvant Chemotherapy with mFOLFIRINOX in Resectable Pancreatic Cancer

Immediate results of neoadjuvant chemotherapy with mFOLFIRINOX regimen in patients with resectable pancreatic cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

IVI. V. VervekinАЗА. А. Захаренко

Discussion

Loading...

Member takes

Overview

Phase II trial demonstrates benefits of neoadjuvant chemotherapy in improving R0 resections and reducing complications in pancreatic cancer patients.

Key Points

  • Neoadjuvant chemotherapy with mFOLFIRINOX significantly improved R0 resections compared to standard treatment.
  • The study showed lower rates of complications and lymphovascular invasion in the neoadjuvant chemotherapy group.
  • Patients receiving neoadjuvant chemotherapy had a higher frequency of negative lymph node status after treatment.
  • These immediate outcomes suggest neoadjuvant chemotherapy may enhance surgical results for resectable pancreatic cancer.

Cite This Study

Vervekin et al. (2025) studied this question.

synapsesocial.com/papers/68de68e583cbc991d0a20fd9https://doi.org/10.21294/1814-4861-2025-24-4-43-53
View Full Paper
Ask AI
Bookmark
Share